- Published on
Ophthalmology – Anterior Basement Membrane Dystrophy
Anterior basement membrane dystrophy (ABMD) is the most common corneal dystrophy and is also known by several names, including map-dot-fingerprint dystrophy, mare’s tail dystrophy, and Cogan’s microcystic dystrophy. It is characterized by abnormalities in the corneal epithelial basement membrane that lead to irregularities of the corneal surface. Clinically, it is most commonly associated with two distinct presentations: recurrent painful corneal erosions and visual disturbance due to an irregular corneal surface, and management differs depending on which presentation predominates.
ABMD is relatively common, affecting up to 10% of the adult population in the United States, with a higher prevalence in women. It typically presents in the fourth or fifth decade of life and may gradually worsen over time. The condition is usually inherited in an autosomal dominant pattern. It may coexist with other ocular surface disorders, such as Fuchs’ endothelial dystrophy, and can be exacerbated by chronic blepharitis.
The underlying pathophysiology involves abnormalities in the epithelial basement membrane, including thickening, reduplication, and extension into the overlying epithelium. This leads to poor adhesion between the epithelium and underlying layers, as well as entrapment of cellular debris within cyst-like structures. These structural abnormalities result in an irregular corneal surface and predispose the epithelium to recurrent breakdown.
Patients typically present in one of two ways. The first is with recurrent corneal erosions, often characterized by sudden onset of pain upon awakening, accompanied by foreign body sensation, tearing, and photophobia. This occurs because the eyelid adheres to the poorly attached epithelium during sleep and disrupts it when opening. The second presentation involves gradual visual decline due to irregular astigmatism from the abnormal epithelial surface, sometimes accompanied by mild irritation.
On examination, findings vary depending on the presentation. In cases of recurrent erosion, there may be a localized area of loose or absent epithelium along with surrounding characteristic changes of ABMD. In cases presenting with visual disturbance, slit-lamp examination reveals classic map, dot, and fingerprint patterns within the corneal epithelium, often over the visual axis, leading to surface irregularity. Diagnostic evaluation includes visual acuity testing and slit-lamp examination, with corneal topography often demonstrating irregular mires and increased surface irregularity. Anterior segment optical coherence tomography can further delineate epithelial and basement membrane abnormalities. A rigid gas-permeable contact lens trial may help confirm that visual symptoms are due to corneal surface irregularity if vision improves significantly with the lens.
The differential diagnosis depends on the clinical presentation. Painful presentations must be distinguished from other causes of ocular surface irritation such as dry eye disease, infectious or chemical keratitis, trauma, and blepharitis. Visual disturbance must be differentiated from other causes of decreased vision, including cataract, macular disease, optic neuropathy, and other corneal pathologies.
Management is tailored to the presenting symptoms. For recurrent erosions, first-line treatment focuses on aggressive lubrication with artificial tears, gels, or ointments, particularly at bedtime, and advising patients to open their eyes slowly upon waking. Hypertonic saline ointments may be used to reduce epithelial edema. Additional measures include punctal occlusion to improve tear retention and therapeutic bandage contact lenses to protect the corneal surface. Topical nonsteroidal anti-inflammatory drugs and cyclosporine may be used to control inflammation and improve tear production.
For cases that are refractory or recurrent, procedural interventions may be considered. These include mechanical debridement of the epithelium with a diamond-dusted burr, ethanol epitheliectomy, or phototherapeutic keratectomy, all of which aim to improve epithelial adherence and reduce recurrence of erosions.
In patients with visually significant disease, treatment focuses on improving the corneal surface. Superficial keratectomy is commonly performed to remove the abnormal epithelium and irregular basement membrane over the visual axis, allowing regeneration of a smoother epithelial surface. Unlike treatment for erosions, aggressive polishing of Bowman’s layer is generally avoided to reduce the risk of scarring. A bandage contact lens is typically placed postoperatively, and topical antibiotics, steroids, and anti-inflammatory medications are used during healing.
Follow-up is based on symptom recurrence and response to treatment, and interventions may be repeated if necessary. The overall prognosis is excellent for both pain and visual symptoms with appropriate management. However, complications such as secondary infection or subepithelial scarring can occur, particularly following surgical intervention.
Anterior basement membrane dystrophy (ABMD) is the most common corneal dystrophy and is also known by several names, including map-dot-fingerprint dystrophy, mare’s tail dystrophy, and Cogan’s microcystic dystrophy. It is characterized by abnormalities in the corneal epithelial basement membrane that lead to irregularities of the corneal surface. Clinically, it is most commonly associated with two distinct presentations: recurrent painful corneal erosions and visual disturbance due to an irregular corneal surface, and management differs depending on which presentation predominates.
ABMD is relatively common, affecting up to 10% of the adult population in the United States, with a higher prevalence in women. It typically presents in the fourth or fifth decade of life and may gradually worsen over time. The condition is usually inherited in an autosomal dominant pattern. It may coexist with other ocular surface disorders, such as Fuchs’ endothelial dystrophy, and can be exacerbated by chronic blepharitis.
The underlying pathophysiology involves abnormalities in the epithelial basement membrane, including thickening, reduplication, and extension into the overlying epithelium. This leads to poor adhesion between the epithelium and underlying layers, as well as entrapment of cellular debris within cyst-like structures. These structural abnormalities result in an irregular corneal surface and predispose the epithelium to recurrent breakdown.
Patients typically present in one of two ways. The first is with recurrent corneal erosions, often characterized by sudden onset of pain upon awakening, accompanied by foreign body sensation, tearing, and photophobia. This occurs because the eyelid adheres to the poorly attached epithelium during sleep and disrupts it when opening. The second presentation involves gradual visual decline due to irregular astigmatism from the abnormal epithelial surface, sometimes accompanied by mild irritation.
On examination, findings vary depending on the presentation. In cases of recurrent erosion, there may be a localized area of loose or absent epithelium along with surrounding characteristic changes of ABMD. In cases presenting with visual disturbance, slit-lamp examination reveals classic map, dot, and fingerprint patterns within the corneal epithelium, often over the visual axis, leading to surface irregularity. Diagnostic evaluation includes visual acuity testing and slit-lamp examination, with corneal topography often demonstrating irregular mires and increased surface irregularity. Anterior segment optical coherence tomography can further delineate epithelial and basement membrane abnormalities. A rigid gas-permeable contact lens trial may help confirm that visual symptoms are due to corneal surface irregularity if vision improves significantly with the lens.
The differential diagnosis depends on the clinical presentation. Painful presentations must be distinguished from other causes of ocular surface irritation such as dry eye disease, infectious or chemical keratitis, trauma, and blepharitis. Visual disturbance must be differentiated from other causes of decreased vision, including cataract, macular disease, optic neuropathy, and other corneal pathologies.
Management is tailored to the presenting symptoms. For recurrent erosions, first-line treatment focuses on aggressive lubrication with artificial tears, gels, or ointments, particularly at bedtime, and advising patients to open their eyes slowly upon waking. Hypertonic saline ointments may be used to reduce epithelial edema. Additional measures include punctal occlusion to improve tear retention and therapeutic bandage contact lenses to protect the corneal surface. Topical nonsteroidal anti-inflammatory drugs and cyclosporine may be used to control inflammation and improve tear production.
For cases that are refractory or recurrent, procedural interventions may be considered. These include mechanical debridement of the epithelium with a diamond-dusted burr, ethanol epitheliectomy, or phototherapeutic keratectomy, all of which aim to improve epithelial adherence and reduce recurrence of erosions.
In patients with visually significant disease, treatment focuses on improving the corneal surface. Superficial keratectomy is commonly performed to remove the abnormal epithelium and irregular basement membrane over the visual axis, allowing regeneration of a smoother epithelial surface. Unlike treatment for erosions, aggressive polishing of Bowman’s layer is generally avoided to reduce the risk of scarring. A bandage contact lens is typically placed postoperatively, and topical antibiotics, steroids, and anti-inflammatory medications are used during healing.
Follow-up is based on symptom recurrence and response to treatment, and interventions may be repeated if necessary. The overall prognosis is excellent for both pain and visual symptoms with appropriate management. However, complications such as secondary infection or subepithelial scarring can occur, particularly following surgical intervention.
- Published on
Ophthalmology – Arcus Senilis
Arcus senilis is a common ocular finding characterized by a yellowish-white ring of lipid deposition in the peripheral cornea, separated from the limbus by a narrow clear zone. It is most frequently seen in older adults and is considered a benign, age-related change that does not affect vision or require treatment. In younger individuals, however, the presence of arcus—often termed arcus juvenilis—may indicate underlying systemic conditions such as hyperlipidemia and increased cardiovascular risk.
The prevalence of arcus senilis increases with age, affecting a significant proportion of individuals over 50 years old, with estimates around 65%. It is more commonly observed in men and in individuals of African descent. While aging is the primary risk factor in older patients, early onset arcus is strongly associated with disorders of lipid metabolism, particularly familial hypercholesterolemia, an autosomal dominant condition. In such cases, the development of arcus reflects the duration of lipid abnormalities rather than their severity.
Pathophysiologically, arcus senilis results from the deposition of lipids—including cholesterol, cholesterol esters, triglycerides, and phospholipids—within the corneal stroma. These deposits occur primarily in both superficial (Bowman’s membrane) and deep (Descemet’s membrane) layers, forming characteristic wedge-shaped opacities that eventually merge into a circumferential ring. Despite these structural changes, corneal transparency in the visual axis remains unaffected, which is why vision is preserved.
Clinically, patients are usually asymptomatic and may notice only a change in the appearance of their eyes, sometimes describing a lighter ring around the iris. On examination, the arcus appears as a well-defined peripheral ring with a clear zone adjacent to the limbus. It typically begins as superior and inferior arcs that gradually extend to form a complete 360-degree ring. Slit-lamp examination helps to better visualize the depth and distribution of lipid deposits.
Although arcus senilis itself does not impair vision, its clinical significance lies in its association with systemic disease in younger patients. In individuals under 50 years of age, especially men, it is considered a marker for hyperlipidemia and may be associated with increased risk of coronary artery disease and cardiovascular mortality. In children, arcus may be linked to congenital ocular anomalies or inherited lipid disorders, necessitating further evaluation.
Diagnosis is primarily clinical, but in younger patients, laboratory evaluation including serum lipid profile is essential. Additional cardiovascular assessment may be warranted depending on risk factors, including evaluation for hypertension, diabetes, smoking history, and family history of cardiovascular disease. In some cases, further investigations such as electrocardiography or stress testing may be indicated.
The differential diagnosis includes other peripheral corneal rings or opacities such as the Kayser–Fleischer ring seen in Wilson’s disease, band keratopathy from calcium deposition, limbal girdle of Vogt, Terrien’s marginal degeneration, and corneal changes associated with metabolic disorders like lecithin-cholesterol acyltransferase deficiency. These conditions can usually be distinguished based on clinical appearance, location, associated symptoms, and systemic findings.
Management of arcus senilis itself is not required, as it is a benign and non-progressive condition in older adults. However, in patients younger than 50 years, identification of arcus should prompt evaluation for underlying lipid abnormalities and cardiovascular risk factors. Patient education is important, with reassurance provided to older individuals and appropriate counseling and referral offered to younger patients for systemic evaluation.
The prognosis is excellent in terms of ocular health, as arcus senilis does not affect vision. Its significance lies primarily as a potential clinical marker for systemic disease in younger individuals, where early detection and management of associated conditions can have important long-term health benefits.
Arcus senilis is a common ocular finding characterized by a yellowish-white ring of lipid deposition in the peripheral cornea, separated from the limbus by a narrow clear zone. It is most frequently seen in older adults and is considered a benign, age-related change that does not affect vision or require treatment. In younger individuals, however, the presence of arcus—often termed arcus juvenilis—may indicate underlying systemic conditions such as hyperlipidemia and increased cardiovascular risk.
The prevalence of arcus senilis increases with age, affecting a significant proportion of individuals over 50 years old, with estimates around 65%. It is more commonly observed in men and in individuals of African descent. While aging is the primary risk factor in older patients, early onset arcus is strongly associated with disorders of lipid metabolism, particularly familial hypercholesterolemia, an autosomal dominant condition. In such cases, the development of arcus reflects the duration of lipid abnormalities rather than their severity.
Pathophysiologically, arcus senilis results from the deposition of lipids—including cholesterol, cholesterol esters, triglycerides, and phospholipids—within the corneal stroma. These deposits occur primarily in both superficial (Bowman’s membrane) and deep (Descemet’s membrane) layers, forming characteristic wedge-shaped opacities that eventually merge into a circumferential ring. Despite these structural changes, corneal transparency in the visual axis remains unaffected, which is why vision is preserved.
Clinically, patients are usually asymptomatic and may notice only a change in the appearance of their eyes, sometimes describing a lighter ring around the iris. On examination, the arcus appears as a well-defined peripheral ring with a clear zone adjacent to the limbus. It typically begins as superior and inferior arcs that gradually extend to form a complete 360-degree ring. Slit-lamp examination helps to better visualize the depth and distribution of lipid deposits.
Although arcus senilis itself does not impair vision, its clinical significance lies in its association with systemic disease in younger patients. In individuals under 50 years of age, especially men, it is considered a marker for hyperlipidemia and may be associated with increased risk of coronary artery disease and cardiovascular mortality. In children, arcus may be linked to congenital ocular anomalies or inherited lipid disorders, necessitating further evaluation.
Diagnosis is primarily clinical, but in younger patients, laboratory evaluation including serum lipid profile is essential. Additional cardiovascular assessment may be warranted depending on risk factors, including evaluation for hypertension, diabetes, smoking history, and family history of cardiovascular disease. In some cases, further investigations such as electrocardiography or stress testing may be indicated.
The differential diagnosis includes other peripheral corneal rings or opacities such as the Kayser–Fleischer ring seen in Wilson’s disease, band keratopathy from calcium deposition, limbal girdle of Vogt, Terrien’s marginal degeneration, and corneal changes associated with metabolic disorders like lecithin-cholesterol acyltransferase deficiency. These conditions can usually be distinguished based on clinical appearance, location, associated symptoms, and systemic findings.
Management of arcus senilis itself is not required, as it is a benign and non-progressive condition in older adults. However, in patients younger than 50 years, identification of arcus should prompt evaluation for underlying lipid abnormalities and cardiovascular risk factors. Patient education is important, with reassurance provided to older individuals and appropriate counseling and referral offered to younger patients for systemic evaluation.
The prognosis is excellent in terms of ocular health, as arcus senilis does not affect vision. Its significance lies primarily as a potential clinical marker for systemic disease in younger individuals, where early detection and management of associated conditions can have important long-term health benefits.
- Published on
Ophthalmology – Anisometropia
Anisometropia is defined as a difference in refractive error between the two eyes and is one of the most common causes of amblyopia. It becomes particularly amblyogenic when the interocular difference exceeds certain thresholds, such as more than 1.50 diopters of hyperopia, more than 1.00 diopter of astigmatism, or more than 6.00 diopters of myopia. Two main forms are recognized: spherical equivalent anisometropia and astigmatic anisometropia. Because of unequal image clarity between the eyes, the brain preferentially uses the clearer image, leading to suppression of the blurrier eye and impaired visual development.
Anisometropia is relatively common, with a prevalence ranging from 1% to 11% of the population. Among affected individuals, approximately 25–60% develop amblyopia. The condition may change during childhood, but larger degrees of anisometropia, particularly greater than 3 diopters, are more likely to persist. Early detection is critical, as the risk of amblyopia increases with age if untreated, with a significant proportion of young children with anisometropia developing amblyopia over time.
Risk factors include prematurity, especially in association with retinopathy of prematurity, as well as congenital conditions such as ptosis, coloboma, cataract, congenital glaucoma, and microphthalmia. Any condition that leads to asymmetric visual input between the eyes in early life can predispose to anisometropia. Although there is no clear inheritance pattern, a family history increases risk, often reflecting the inheritance of underlying ocular conditions rather than anisometropia itself.
The underlying pathophysiology involves unequal visual input to the brain, which disrupts normal binocular visual development. This imbalance leads to suppression of the image from the more defocused eye and reduced stimulation of the corresponding neurons in the visual cortex. Over time, this results in amblyopia, characterized by decreased visual acuity that cannot be explained by structural abnormalities alone. Functional imaging studies have demonstrated reduced activation in the visual cortex and lateral geniculate nucleus corresponding to the amblyopic eye.
Clinically, anisometropia may present with unequal refractive prescriptions between the eyes or unilateral visual impairment. In some cases, it is detected during routine screening, particularly in children who may not report symptoms. A thorough eye examination is essential, including measurement of visual acuity and a complete dilated examination to exclude other causes of reduced vision. Cycloplegic refraction is critical for accurately identifying the degree of refractive difference between the eyes. Reduced contrast sensitivity may also be observed in anisometropic amblyopia.
The differential diagnosis includes any ocular or neurologic condition that can cause unilateral or asymmetric visual impairment, such as retinal disease, optic nerve pathology, or cortical visual disorders. It is also important to consider structural causes of refractive asymmetry, including differences in axial length, corneal curvature, or lens power.
Management focuses on correcting the refractive error and preventing or treating amblyopia. Spectacle correction is the first-line treatment and may alone lead to significant improvement in visual acuity, with many patients showing improvement over several months. In cases where amblyopia persists, additional therapy is required, typically involving occlusion (patching) of the better-seeing eye or pharmacologic penalization with atropine. Both approaches aim to stimulate use of the amblyopic eye and promote visual development. Contact lenses may be preferred in cases of high anisometropia to reduce image size differences (aniseikonia) and improve cosmetic acceptance.
Follow-up is essential to monitor visual improvement and ensure compliance with treatment. Younger children require more frequent monitoring due to the rapid changes in visual development and the risk of amblyopia. Care must also be taken to avoid occlusion amblyopia in the treated eye. Referral for surgical intervention may be necessary if an underlying structural cause such as cataract or ptosis is identified.
The prognosis is generally good with early detection and appropriate treatment. Many patients experience significant improvement in visual acuity with spectacles alone, and further gains can be achieved with amblyopia therapy. However, delayed treatment reduces the likelihood of full recovery, emphasizing the importance of early screening and intervention. Potential complications include persistent amblyopia and, less commonly, iatrogenic visual loss in the better eye due to overtreatment.
Anisometropia is defined as a difference in refractive error between the two eyes and is one of the most common causes of amblyopia. It becomes particularly amblyogenic when the interocular difference exceeds certain thresholds, such as more than 1.50 diopters of hyperopia, more than 1.00 diopter of astigmatism, or more than 6.00 diopters of myopia. Two main forms are recognized: spherical equivalent anisometropia and astigmatic anisometropia. Because of unequal image clarity between the eyes, the brain preferentially uses the clearer image, leading to suppression of the blurrier eye and impaired visual development.
Anisometropia is relatively common, with a prevalence ranging from 1% to 11% of the population. Among affected individuals, approximately 25–60% develop amblyopia. The condition may change during childhood, but larger degrees of anisometropia, particularly greater than 3 diopters, are more likely to persist. Early detection is critical, as the risk of amblyopia increases with age if untreated, with a significant proportion of young children with anisometropia developing amblyopia over time.
Risk factors include prematurity, especially in association with retinopathy of prematurity, as well as congenital conditions such as ptosis, coloboma, cataract, congenital glaucoma, and microphthalmia. Any condition that leads to asymmetric visual input between the eyes in early life can predispose to anisometropia. Although there is no clear inheritance pattern, a family history increases risk, often reflecting the inheritance of underlying ocular conditions rather than anisometropia itself.
The underlying pathophysiology involves unequal visual input to the brain, which disrupts normal binocular visual development. This imbalance leads to suppression of the image from the more defocused eye and reduced stimulation of the corresponding neurons in the visual cortex. Over time, this results in amblyopia, characterized by decreased visual acuity that cannot be explained by structural abnormalities alone. Functional imaging studies have demonstrated reduced activation in the visual cortex and lateral geniculate nucleus corresponding to the amblyopic eye.
Clinically, anisometropia may present with unequal refractive prescriptions between the eyes or unilateral visual impairment. In some cases, it is detected during routine screening, particularly in children who may not report symptoms. A thorough eye examination is essential, including measurement of visual acuity and a complete dilated examination to exclude other causes of reduced vision. Cycloplegic refraction is critical for accurately identifying the degree of refractive difference between the eyes. Reduced contrast sensitivity may also be observed in anisometropic amblyopia.
The differential diagnosis includes any ocular or neurologic condition that can cause unilateral or asymmetric visual impairment, such as retinal disease, optic nerve pathology, or cortical visual disorders. It is also important to consider structural causes of refractive asymmetry, including differences in axial length, corneal curvature, or lens power.
Management focuses on correcting the refractive error and preventing or treating amblyopia. Spectacle correction is the first-line treatment and may alone lead to significant improvement in visual acuity, with many patients showing improvement over several months. In cases where amblyopia persists, additional therapy is required, typically involving occlusion (patching) of the better-seeing eye or pharmacologic penalization with atropine. Both approaches aim to stimulate use of the amblyopic eye and promote visual development. Contact lenses may be preferred in cases of high anisometropia to reduce image size differences (aniseikonia) and improve cosmetic acceptance.
Follow-up is essential to monitor visual improvement and ensure compliance with treatment. Younger children require more frequent monitoring due to the rapid changes in visual development and the risk of amblyopia. Care must also be taken to avoid occlusion amblyopia in the treated eye. Referral for surgical intervention may be necessary if an underlying structural cause such as cataract or ptosis is identified.
The prognosis is generally good with early detection and appropriate treatment. Many patients experience significant improvement in visual acuity with spectacles alone, and further gains can be achieved with amblyopia therapy. However, delayed treatment reduces the likelihood of full recovery, emphasizing the importance of early screening and intervention. Potential complications include persistent amblyopia and, less commonly, iatrogenic visual loss in the better eye due to overtreatment.
- Published on
Infectious Disease and Microbiology: Hemolytic–Uremic Syndrome (HUS)
Hemolytic–uremic syndrome (HUS) is a serious clinical condition characterized by a triad of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. It is most commonly associated with infection by Shiga toxin–producing bacteria, particularly Escherichia coli O157:H7 (EHEC). HUS primarily affects young children but can occur at any age and is a major cause of acute kidney injury in pediatric populations.
Epidemiologically, HUS is closely linked to infections caused by enterohemorrhagic E. coli, with an incidence of approximately 1–5 cases per 100,000 people annually in industrialized countries. The infection is more common in children under 5 years old and tends to peak during warmer months, particularly from June to September. Although many individuals infected with EHEC develop only mild gastrointestinal symptoms, about 8% of cases during outbreaks progress to HUS, especially in vulnerable populations such as young children and the elderly.
Transmission is primarily food-borne and is strongly associated with the consumption of undercooked ground beef, unpasteurized milk, contaminated water, and fresh produce such as apples or melons. Cattle serve as the main reservoir, often carrying the organism asymptomatically in their intestines. Infection can also spread through person-to-person contact, particularly in settings such as daycare centers and nursing homes. Proper food handling, cooking, and hygiene practices are essential preventive measures.
The pathophysiology of HUS involves the production of Shiga-like toxin by EHEC. This toxin damages endothelial cells, particularly in the kidneys, leading to inflammation, platelet activation, and formation of microthrombi in small blood vessels. These processes result in mechanical destruction of red blood cells (hemolysis), platelet consumption (thrombocytopenia), and reduced renal perfusion, ultimately causing acute kidney injury.
Clinically, infection typically begins with abdominal cramps and watery diarrhea, which progresses within 24 hours to bloody diarrhea in most patients. Nausea and vomiting are common, while fever is usually absent or mild. As HUS develops, signs such as decreased urine output (oliguria), pallor from anemia, and fatigue become evident. The drop in hematocrit and platelet count are early laboratory indicators of disease progression.
Diagnosis is based on clinical findings and laboratory confirmation. Stool cultures using special media are required to identify EHEC, as routine cultures may miss the organism. Laboratory findings in HUS include anemia with fragmented red blood cells (schistocytes), elevated lactate dehydrogenase (LDH), low haptoglobin, thrombocytopenia, and elevated creatinine levels indicating renal impairment. Urinalysis may show hematuria and proteinuria.
Management of HUS is primarily supportive. Antibiotics are generally not recommended in EHEC infections, as they may increase toxin release and worsen the condition. Similarly, antimotility agents should be avoided because they can enhance toxin absorption. Treatment focuses on maintaining fluid and electrolyte balance, managing renal failure with dialysis if necessary, and providing blood transfusions when indicated. In severe cases, plasmapheresis may be used.
The prognosis of HUS varies depending on severity and patient factors. Despite advances in supportive care, mortality rates range from 5% to 20%, with higher rates in older adults. Among survivors, long-term complications are common, including chronic kidney disease and hypertension, with many patients eventually requiring dialysis or kidney transplantation.
Complications of HUS include severe anemia, thrombocytopenia, electrolyte disturbances, rhabdomyolysis, and permanent renal damage. Additionally, EHEC infection itself may cause hemorrhagic colitis or, less commonly, conditions such as thrombotic thrombocytopenic purpura. Early recognition and supportive management are critical to improving outcomes.
- Published on
Ophthalmology – Acute Retinal Necrosis (Necrotizing Herpetic Retinitis)
Acute retinal necrosis is a severe, vision-threatening infectious retinitis caused by members of the herpes virus family, most commonly varicella zoster virus and herpes simplex virus. It is characterized by a combination of anterior uveitis, vitritis, and rapidly progressive peripheral retinal necrosis that spreads circumferentially and posteriorly, often accompanied by occlusive retinal vasculitis and a high risk of retinal detachment. Despite being a rare condition, with an estimated incidence of approximately 1 case per 1.6–2.0 million individuals, it typically affects otherwise healthy, immunocompetent individuals and shows a bimodal age distribution, most commonly occurring around ages 20 and 50.
Risk factors include a history of herpetic infections such as herpes simplex keratitis, herpes zoster ophthalmicus, cold sores, chickenpox, encephalitis, or shingles. Although immunodeficiency may contribute, most cases occur in immunocompetent patients. Genetic predispositions have been described, with certain HLA types associated with different populations and disease severity. The pathophysiology involves reactivation or primary infection of herpes viruses, which travel via axonal pathways to the retina, leading to viral replication within retinal cells. This results in full-thickness retinal necrosis, intranuclear viral inclusions, and both granulomatous and non-granulomatous inflammation affecting ocular tissues.
Patients may initially present with relatively mild symptoms such as eye redness, irritation, photophobia, floaters, and periorbital pain, although many experience sudden vision loss. On examination, there is often evidence of anterior uveitis, including keratic precipitates and inflammatory activity in the anterior chamber, as well as vitritis. Within days, characteristic posterior segment findings develop, including multifocal, well-demarcated patches of yellow-white retinal necrosis in the peripheral retina. These lesions rapidly progress circumferentially and posteriorly, often sparing the macula initially. Retinal vasculitis with vascular sheathing and hemorrhages may also be present. Over time, complications such as proliferative vitreoretinopathy lead to retinal breaks and rhegmatogenous retinal detachment, which occurs in more than half of cases, typically within one to two months. Bilateral involvement is seen in about 20% of patients at presentation, and without treatment, the second eye may become affected within months.
Diagnosis is primarily clinical, guided by established criteria that include peripheral retinal necrosis, rapid progression, occlusive vasculopathy, and significant intraocular inflammation. Laboratory confirmation can be achieved using polymerase chain reaction testing of aqueous or vitreous samples, which provides high sensitivity and specificity for identifying viral DNA. Other diagnostic methods, such as antibody testing or cultures, may support the diagnosis but are less definitive. Serial fundus photography is useful for monitoring disease progression, and careful examination of both eyes is essential due to the risk of bilateral spread.
The differential diagnosis includes other infectious and inflammatory retinal conditions such as progressive outer retinal necrosis, cytomegalovirus retinitis, toxoplasmosis, syphilitic retinitis, Behçet disease, sarcoidosis, intraocular lymphoma, and fungal endophthalmitis. Management requires urgent antiviral therapy to limit retinal destruction and reduce complications. Treatment traditionally involved intravenous acyclovir followed by prolonged oral therapy, but newer regimens include oral antivirals such as valacyclovir or famciclovir, often combined with intravitreal antiviral injections such as foscarnet or ganciclovir. Adjunctive corticosteroids are frequently used to control inflammation, and topical steroids are commonly administered for anterior segment involvement.
Patients should be urgently referred to a retinal or uveitis specialist due to the aggressive nature of the disease and the potential need for surgical intervention. Prophylactic laser retinopexy may be considered to reduce the risk of retinal detachment, although its benefit remains debated. Vitrectomy is indicated in cases of dense vitreous opacities, hemorrhage, or established retinal detachment. Close monitoring is essential, particularly during the early course, to detect progression, bilateral involvement, or complications.
The prognosis remains guarded despite advances in antiviral therapy, with many patients experiencing significant vision loss. Retinal detachment is the most common and serious complication, and visual outcomes are often poor, with a substantial proportion of patients developing vision worse than 20/200 over time. Other complications include optic nerve involvement, vitreous hemorrhage, retinal neovascularization, and eventual blindness. Early recognition and aggressive treatment are critical to improving outcomes and preserving vision.
Acute retinal necrosis is a severe, vision-threatening infectious retinitis caused by members of the herpes virus family, most commonly varicella zoster virus and herpes simplex virus. It is characterized by a combination of anterior uveitis, vitritis, and rapidly progressive peripheral retinal necrosis that spreads circumferentially and posteriorly, often accompanied by occlusive retinal vasculitis and a high risk of retinal detachment. Despite being a rare condition, with an estimated incidence of approximately 1 case per 1.6–2.0 million individuals, it typically affects otherwise healthy, immunocompetent individuals and shows a bimodal age distribution, most commonly occurring around ages 20 and 50.
Risk factors include a history of herpetic infections such as herpes simplex keratitis, herpes zoster ophthalmicus, cold sores, chickenpox, encephalitis, or shingles. Although immunodeficiency may contribute, most cases occur in immunocompetent patients. Genetic predispositions have been described, with certain HLA types associated with different populations and disease severity. The pathophysiology involves reactivation or primary infection of herpes viruses, which travel via axonal pathways to the retina, leading to viral replication within retinal cells. This results in full-thickness retinal necrosis, intranuclear viral inclusions, and both granulomatous and non-granulomatous inflammation affecting ocular tissues.
Patients may initially present with relatively mild symptoms such as eye redness, irritation, photophobia, floaters, and periorbital pain, although many experience sudden vision loss. On examination, there is often evidence of anterior uveitis, including keratic precipitates and inflammatory activity in the anterior chamber, as well as vitritis. Within days, characteristic posterior segment findings develop, including multifocal, well-demarcated patches of yellow-white retinal necrosis in the peripheral retina. These lesions rapidly progress circumferentially and posteriorly, often sparing the macula initially. Retinal vasculitis with vascular sheathing and hemorrhages may also be present. Over time, complications such as proliferative vitreoretinopathy lead to retinal breaks and rhegmatogenous retinal detachment, which occurs in more than half of cases, typically within one to two months. Bilateral involvement is seen in about 20% of patients at presentation, and without treatment, the second eye may become affected within months.
Diagnosis is primarily clinical, guided by established criteria that include peripheral retinal necrosis, rapid progression, occlusive vasculopathy, and significant intraocular inflammation. Laboratory confirmation can be achieved using polymerase chain reaction testing of aqueous or vitreous samples, which provides high sensitivity and specificity for identifying viral DNA. Other diagnostic methods, such as antibody testing or cultures, may support the diagnosis but are less definitive. Serial fundus photography is useful for monitoring disease progression, and careful examination of both eyes is essential due to the risk of bilateral spread.
The differential diagnosis includes other infectious and inflammatory retinal conditions such as progressive outer retinal necrosis, cytomegalovirus retinitis, toxoplasmosis, syphilitic retinitis, Behçet disease, sarcoidosis, intraocular lymphoma, and fungal endophthalmitis. Management requires urgent antiviral therapy to limit retinal destruction and reduce complications. Treatment traditionally involved intravenous acyclovir followed by prolonged oral therapy, but newer regimens include oral antivirals such as valacyclovir or famciclovir, often combined with intravitreal antiviral injections such as foscarnet or ganciclovir. Adjunctive corticosteroids are frequently used to control inflammation, and topical steroids are commonly administered for anterior segment involvement.
Patients should be urgently referred to a retinal or uveitis specialist due to the aggressive nature of the disease and the potential need for surgical intervention. Prophylactic laser retinopexy may be considered to reduce the risk of retinal detachment, although its benefit remains debated. Vitrectomy is indicated in cases of dense vitreous opacities, hemorrhage, or established retinal detachment. Close monitoring is essential, particularly during the early course, to detect progression, bilateral involvement, or complications.
The prognosis remains guarded despite advances in antiviral therapy, with many patients experiencing significant vision loss. Retinal detachment is the most common and serious complication, and visual outcomes are often poor, with a substantial proportion of patients developing vision worse than 20/200 over time. Other complications include optic nerve involvement, vitreous hemorrhage, retinal neovascularization, and eventual blindness. Early recognition and aggressive treatment are critical to improving outcomes and preserving vision.
- Published on
Ophthalmology – Acute Anterior Uveitis
Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.
A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.
Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.
Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.
Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.
Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.
Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.
Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.
A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.
Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.
Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.
Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.
Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.
Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.
- Published on
Ophthalmology – Acne Rosacea
Acne rosacea is a chronic inflammatory acneiform disorder that primarily affects the central face, including the nose, cheeks, chin, forehead, and may also involve the eyelids and ocular surface. It commonly presents with facial flushing, persistent erythema, papules, pustules, and a sensation of burning or stinging, often accompanied by dry skin. Ocular involvement is frequent and may manifest as blepharoconjunctivitis with meibomian gland dysfunction, lid margin telangiectasia, recurrent hordeola or chalazia, conjunctival hyperemia, and irritation. In more severe cases, the cornea may be affected, leading to punctate epithelial keratitis, vascularization, infiltration, ulceration, or even perforation. Less commonly, inflammation may extend to the episclera, sclera, or iris.
Rosacea affects approximately 1 in 20 individuals, most commonly between the ages of 30 and 60 years, with no clear sex predilection. It is thought to be more prevalent in fair-skinned individuals of European or Celtic descent, although this may be underrecognized in darker skin due to masking by pigmentation. While no single causative gene has been identified, there is often a familial tendency. The exact etiology remains unclear, with proposed contributing factors including vascular dysregulation, immune and inflammatory mechanisms, environmental triggers, and possibly microorganisms such as Demodex folliculorum. Pathophysiologically, abnormal vascular responses lead to vasodilation and leakage of plasma, which promotes inflammation.
Patients often report a history of facial flushing triggered by environmental or lifestyle factors such as sun exposure, wind, extreme temperatures, exercise, stress, alcohol, or spicy foods. On examination, characteristic findings include diffuse erythema, telangiectasias, inflammatory papules and pustules, and in advanced cases, hypertrophy of sebaceous glands resulting in rhinophyma, which is thickening and purplish discoloration of the nasal skin. Ocular examination may reveal chronic eyelid inflammation, meibomian gland obstruction, and signs of conjunctival or corneal involvement.
Diagnosis is primarily clinical and does not require laboratory testing. Histopathological findings, when assessed, include vascular dilation, perivascular inflammatory infiltrates composed of lymphocytes, plasma cells, and histiocytes, and degeneration of dermal connective tissue with edema and elastosis. In rhinophyma, there is an increase in sebaceous gland tissue. Differential diagnoses include acne vulgaris, lupus erythematosus, seborrheic dermatitis, erysipelas, dermatitis, carcinoid syndrome, tuberculosis, and syphilis.
Management focuses on controlling symptoms and preventing progression, as rosacea is a chronic condition without a definitive cure. First-line treatment typically includes oral tetracyclines such as doxycycline or minocycline, which have both antimicrobial and anti-inflammatory effects. Topical therapies such as metronidazole, azelaic acid, or sodium sulfacetamide may also be used. Lid hygiene is essential in patients with ocular involvement, along with lubricants and, in some cases, short-term topical corticosteroids. More severe or refractory cases may require oral isotretinoin or procedural interventions such as electrocautery for telangiectasias.
Patients should be advised to avoid known triggers, use daily sunscreen, and adopt gentle skincare practices. Dietary modifications, including limiting spicy foods, alcohol, and hot beverages, may help reduce flare-ups. Referral to ophthalmology is important in cases with significant ocular involvement, particularly when there is corneal disease or recurrent eyelid lesions, and dermatology referral may be necessary for severe cutaneous disease or rhinophyma requiring surgical or laser treatment.
Regular follow-up is important to monitor for complications, especially corneal involvement, which can threaten vision if untreated. The overall prognosis is good with appropriate management, although symptoms tend to be chronic and relapsing. Key clinical insights include recognizing that recurrent chalazia or hordeola may indicate underlying ocular rosacea, and that long-term management often relies on a combination of topical and systemic antibiotic therapy along with lifestyle modification.
Acne rosacea is a chronic inflammatory acneiform disorder that primarily affects the central face, including the nose, cheeks, chin, forehead, and may also involve the eyelids and ocular surface. It commonly presents with facial flushing, persistent erythema, papules, pustules, and a sensation of burning or stinging, often accompanied by dry skin. Ocular involvement is frequent and may manifest as blepharoconjunctivitis with meibomian gland dysfunction, lid margin telangiectasia, recurrent hordeola or chalazia, conjunctival hyperemia, and irritation. In more severe cases, the cornea may be affected, leading to punctate epithelial keratitis, vascularization, infiltration, ulceration, or even perforation. Less commonly, inflammation may extend to the episclera, sclera, or iris.
Rosacea affects approximately 1 in 20 individuals, most commonly between the ages of 30 and 60 years, with no clear sex predilection. It is thought to be more prevalent in fair-skinned individuals of European or Celtic descent, although this may be underrecognized in darker skin due to masking by pigmentation. While no single causative gene has been identified, there is often a familial tendency. The exact etiology remains unclear, with proposed contributing factors including vascular dysregulation, immune and inflammatory mechanisms, environmental triggers, and possibly microorganisms such as Demodex folliculorum. Pathophysiologically, abnormal vascular responses lead to vasodilation and leakage of plasma, which promotes inflammation.
Patients often report a history of facial flushing triggered by environmental or lifestyle factors such as sun exposure, wind, extreme temperatures, exercise, stress, alcohol, or spicy foods. On examination, characteristic findings include diffuse erythema, telangiectasias, inflammatory papules and pustules, and in advanced cases, hypertrophy of sebaceous glands resulting in rhinophyma, which is thickening and purplish discoloration of the nasal skin. Ocular examination may reveal chronic eyelid inflammation, meibomian gland obstruction, and signs of conjunctival or corneal involvement.
Diagnosis is primarily clinical and does not require laboratory testing. Histopathological findings, when assessed, include vascular dilation, perivascular inflammatory infiltrates composed of lymphocytes, plasma cells, and histiocytes, and degeneration of dermal connective tissue with edema and elastosis. In rhinophyma, there is an increase in sebaceous gland tissue. Differential diagnoses include acne vulgaris, lupus erythematosus, seborrheic dermatitis, erysipelas, dermatitis, carcinoid syndrome, tuberculosis, and syphilis.
Management focuses on controlling symptoms and preventing progression, as rosacea is a chronic condition without a definitive cure. First-line treatment typically includes oral tetracyclines such as doxycycline or minocycline, which have both antimicrobial and anti-inflammatory effects. Topical therapies such as metronidazole, azelaic acid, or sodium sulfacetamide may also be used. Lid hygiene is essential in patients with ocular involvement, along with lubricants and, in some cases, short-term topical corticosteroids. More severe or refractory cases may require oral isotretinoin or procedural interventions such as electrocautery for telangiectasias.
Patients should be advised to avoid known triggers, use daily sunscreen, and adopt gentle skincare practices. Dietary modifications, including limiting spicy foods, alcohol, and hot beverages, may help reduce flare-ups. Referral to ophthalmology is important in cases with significant ocular involvement, particularly when there is corneal disease or recurrent eyelid lesions, and dermatology referral may be necessary for severe cutaneous disease or rhinophyma requiring surgical or laser treatment.
Regular follow-up is important to monitor for complications, especially corneal involvement, which can threaten vision if untreated. The overall prognosis is good with appropriate management, although symptoms tend to be chronic and relapsing. Key clinical insights include recognizing that recurrent chalazia or hordeola may indicate underlying ocular rosacea, and that long-term management often relies on a combination of topical and systemic antibiotic therapy along with lifestyle modification.
- Published on
Ophthalmology – Achromatopsia
Achromatopsia is a congenital retinal disorder characterized by reduced or absent color vision due to defective cone photoreceptor function. It presents with photophobia, decreased visual acuity, nystagmus, eccentric fixation, and a small central scotoma. The condition may be classified into complete and incomplete forms, depending on the degree of residual cone function. It typically manifests in infancy, often with fine nystagmus and marked light sensitivity, and children may prefer dim lighting, sometimes being described as “night owls.” Visual acuity is usually reduced, commonly around 20/200, and color discrimination is severely impaired.
The condition has an estimated incidence of approximately 1 in 30,000 individuals and follows an autosomal recessive inheritance pattern. Risk factors include consanguinity and a positive family history. Several genetic mutations have been identified, including CNGA3, CNGB3 (notably the Pingelap variant), GNAT2, and others, all affecting proteins involved in cone phototransduction. The underlying pathophysiology involves reduced or absent expression of these proteins in cone photoreceptors, leading to disruption of the normal phototransduction cascade and abnormal cone development.
Clinically, patients exhibit high-frequency nystagmus that may lessen with age, significant photophobia, and reduced visual acuity. Hyperopia may be present, and fundus examination is often normal or shows only subtle changes such as minimal foveal hypoplasia or mild pigmentary alterations. Color vision testing reveals impairment across all axes (protan, deutan, and tritan). Full-field electroretinography typically demonstrates absent or markedly reduced photopic (cone-mediated) responses with relatively preserved scotopic (rod-mediated) responses. Visual field testing may show a small central scotoma, and optical coherence tomography may appear normal or show mild macular thinning. Additional imaging such as fluorescein angiography and fundus autofluorescence is usually normal.
Diagnosis is supported by clinical findings and can be confirmed with molecular genetic testing. Neuroimaging may be considered in atypical cases, particularly when nystagmus presentation is unusual, to exclude intracranial pathology. Histopathologically, there is a reduced number of cones, and the remaining cones are structurally abnormal.
Differential diagnoses include incomplete achromatopsia, which retains partial cone function and better visual acuity; blue-cone monochromatism, which is X-linked and can be differentiated by specialized color testing or electroretinography; cone monochromatism; cone dystrophy, which shows progressive deterioration rather than congenital onset; and cone-rod dystrophy, which includes rod involvement over time. Other considerations include foveal hypoplasia and cerebral achromatopsia, the latter typically associated with neurological events such as trauma or febrile illness.
There is no specific medical treatment for achromatopsia. Management focuses on supportive measures, including the use of dark or tinted glasses or red-tinted contact lenses to reduce photophobia, although these may not always be well tolerated. Low vision aids are beneficial, and children may require educational support such as individualized learning plans. Correction of refractive error is important, and patients should be referred for genetic counseling and low vision services as needed.
Regular follow-up is recommended, particularly in children, with ophthalmic evaluations every 6 to 12 months to monitor visual function and refractive status. The prognosis is generally stable, with visual acuity remaining relatively constant over time, although mild degeneration may occur later in life due to age-related photoreceptor loss. Nystagmus and photophobia may improve slightly with age. The main complications include persistent low vision and significant light sensitivity, which can impact daily functioning and quality of life.
Achromatopsia is a congenital retinal disorder characterized by reduced or absent color vision due to defective cone photoreceptor function. It presents with photophobia, decreased visual acuity, nystagmus, eccentric fixation, and a small central scotoma. The condition may be classified into complete and incomplete forms, depending on the degree of residual cone function. It typically manifests in infancy, often with fine nystagmus and marked light sensitivity, and children may prefer dim lighting, sometimes being described as “night owls.” Visual acuity is usually reduced, commonly around 20/200, and color discrimination is severely impaired.
The condition has an estimated incidence of approximately 1 in 30,000 individuals and follows an autosomal recessive inheritance pattern. Risk factors include consanguinity and a positive family history. Several genetic mutations have been identified, including CNGA3, CNGB3 (notably the Pingelap variant), GNAT2, and others, all affecting proteins involved in cone phototransduction. The underlying pathophysiology involves reduced or absent expression of these proteins in cone photoreceptors, leading to disruption of the normal phototransduction cascade and abnormal cone development.
Clinically, patients exhibit high-frequency nystagmus that may lessen with age, significant photophobia, and reduced visual acuity. Hyperopia may be present, and fundus examination is often normal or shows only subtle changes such as minimal foveal hypoplasia or mild pigmentary alterations. Color vision testing reveals impairment across all axes (protan, deutan, and tritan). Full-field electroretinography typically demonstrates absent or markedly reduced photopic (cone-mediated) responses with relatively preserved scotopic (rod-mediated) responses. Visual field testing may show a small central scotoma, and optical coherence tomography may appear normal or show mild macular thinning. Additional imaging such as fluorescein angiography and fundus autofluorescence is usually normal.
Diagnosis is supported by clinical findings and can be confirmed with molecular genetic testing. Neuroimaging may be considered in atypical cases, particularly when nystagmus presentation is unusual, to exclude intracranial pathology. Histopathologically, there is a reduced number of cones, and the remaining cones are structurally abnormal.
Differential diagnoses include incomplete achromatopsia, which retains partial cone function and better visual acuity; blue-cone monochromatism, which is X-linked and can be differentiated by specialized color testing or electroretinography; cone monochromatism; cone dystrophy, which shows progressive deterioration rather than congenital onset; and cone-rod dystrophy, which includes rod involvement over time. Other considerations include foveal hypoplasia and cerebral achromatopsia, the latter typically associated with neurological events such as trauma or febrile illness.
There is no specific medical treatment for achromatopsia. Management focuses on supportive measures, including the use of dark or tinted glasses or red-tinted contact lenses to reduce photophobia, although these may not always be well tolerated. Low vision aids are beneficial, and children may require educational support such as individualized learning plans. Correction of refractive error is important, and patients should be referred for genetic counseling and low vision services as needed.
Regular follow-up is recommended, particularly in children, with ophthalmic evaluations every 6 to 12 months to monitor visual function and refractive status. The prognosis is generally stable, with visual acuity remaining relatively constant over time, although mild degeneration may occur later in life due to age-related photoreceptor loss. Nystagmus and photophobia may improve slightly with age. The main complications include persistent low vision and significant light sensitivity, which can impact daily functioning and quality of life.
- Published on
Infectious Disease and Microbiology: Hantavirus Pulmonary Syndrome (HPS)
Hantavirus pulmonary syndrome (HPS) is a severe and life-threatening cardiopulmonary disease caused by hantaviruses, most commonly the Sin Nombre virus in North America. First recognized in 1993 in the southwestern United States, the disease is associated with a high mortality rate and rapid clinical deterioration. It primarily affects previously healthy individuals who are exposed to infected rodents.
Epidemiologically, HPS is rare but has been reported in multiple regions across the Americas. Its occurrence is closely linked to the population dynamics of rodents, particularly deer mice and other species such as cotton rats and white-footed mice. Human infection typically results from inhalation of aerosolized particles contaminated with rodent urine, feces, or saliva. Individuals at higher risk include farmers, construction workers, campers, and those cleaning rodent-infested buildings. Although person-to-person transmission is extremely uncommon, it has been reported in certain regions with specific strains such as the Andes virus.
The pathophysiology of HPS involves viral infection of endothelial cells, especially within the lungs, leading to increased vascular permeability. This results in capillary leak syndrome, pulmonary edema, and impaired oxygen exchange. The disease is driven largely by the host immune response rather than direct viral destruction of tissues, leading to pneumonitis, shock, and respiratory failure.
Clinically, the illness begins with a prodromal phase lasting several days, characterized by nonspecific symptoms such as fever, myalgia, fatigue, headache, and sometimes gastrointestinal complaints. This is followed by an abrupt cardiopulmonary phase marked by cough and rapidly progressive shortness of breath, often leading to respiratory failure within a short time. Physical findings include tachypnea, hypoxia, pulmonary crackles, and signs of circulatory shock. Death may occur due to severe hypoxia, shock, or cardiac arrhythmias.
Laboratory evaluation typically reveals leukocytosis with a left shift, thrombocytopenia, hemoconcentration, and atypical lymphocytes. Elevated liver enzymes, creatine phosphokinase, and lactate dehydrogenase are also common. Imaging studies such as chest X-ray or CT scan demonstrate interstitial infiltrates, pulmonary edema, and pleural effusions. Diagnosis is confirmed through serologic testing detecting hantavirus-specific IgM or rising IgG titers, PCR identification of viral RNA, or immunohistochemical detection of viral antigens in tissue samples.
Management of HPS is primarily supportive, as no proven antiviral therapy exists. Patients often require hospitalization and close monitoring, with many needing intensive care, oxygen supplementation, or mechanical ventilation. Broad-spectrum antibiotics are usually started initially until other causes of severe pneumonia are excluded. In critical cases, advanced supportive therapies such as extracorporeal membrane oxygenation (ECMO) may be employed. Prevention relies on minimizing exposure to rodents and their excreta, as no vaccine is currently available.
The prognosis of HPS is guarded, with mortality rates ranging from 35% to 40%, especially in patients with severe disease. Early recognition and aggressive supportive care improve survival. Major complications include acute respiratory distress syndrome, myocardial dysfunction, shock, and death.
- Published on
Ophthalmology – Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among older adults, particularly in developed countries, and is the most common cause of legal blindness in individuals aged 65 years and older in the United States. It is broadly classified into two forms: non-exudative (“dry”) AMD, which accounts for approximately 90% of cases, and exudative (“wet”) AMD, which represents about 10% but is responsible for the majority of severe vision loss. Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity from AMD, characterized by abnormalities in the inner choroidal vasculature, including a branching network of dilated vessels that lead to serous leakage and hemorrhage. PCV is more commonly seen in Asian and African or African American populations, while it is less frequent in Caucasians.
The incidence and prevalence of AMD increase significantly with age. Early AMD rises from about 3.9% in individuals aged 43–54 years to over 20% in those older than 75 years, while late AMD has a 5-year incidence of approximately 0.9%. Overall prevalence of AMD in adults over 40 years is around 9.2%. PCV prevalence varies widely, ranging from 4% to 14%, and may be significantly higher in certain populations, such as Japanese patients diagnosed with AMD. Risk factors for AMD include advancing age, family history, Caucasian race, smoking, hypertension, hyperlipidemia, obesity, and female gender. In contrast, PCV is more strongly associated with ethnicity and age.
Genetic factors play an important role in AMD, with associations identified in genes such as complement factor H (CFH), LOC387715, and HTRA1, with certain variants significantly increasing disease risk. PCV shares some genetic associations, particularly involving LOC387715 and HTRA1. The pathophysiology of AMD is multifactorial and includes degeneration of the retinal pigment epithelium (RPE), accumulation of photoreceptor debris forming drusen, reduced choroidal circulation leading to ischemia, and genetic susceptibility. In the exudative form, abnormal choroidal neovascular membranes develop beneath the retina or RPE, causing leakage and hemorrhage. In PCV, abnormalities in the inner choroidal vasculature result in polyp-like dilations and vascular networks that leak or bleed beneath the RPE.
Patients with AMD or PCV may present with central visual disturbances such as blurring, distortion (metamorphopsia), central scotomas, or may be asymptomatic in early stages. On examination, non-exudative AMD is characterized by drusen, pigmentary changes in the RPE, and eventual retinal thinning or geographic atrophy. Exudative AMD may show subretinal or intraretinal fluid, hemorrhage, lipid exudates, pigment epithelial detachment, or retinal pigment epithelial tears. PCV should be suspected in patients with exudative maculopathy, particularly in non-Caucasian individuals, those with peripapillary lesions, or cases with minimal drusen in the fellow eye.
Diagnosis relies heavily on imaging. Optical coherence tomography (OCT) is essential for identifying fluid, retinal thickening, and monitoring disease progression. Fluorescein angiography is used to identify and characterize choroidal neovascularization in AMD. Indocyanine green angiography is particularly useful in PCV for visualizing the characteristic polypoidal vascular lesions and branching networks. These imaging modalities are also critical in guiding treatment decisions and monitoring response to therapy.
Management of AMD depends on the stage and type of disease. For exudative AMD, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab and ranibizumab are the mainstay of treatment and have significantly improved visual outcomes. Additional therapies may include photodynamic therapy, thermal laser for selected cases, intravitreal steroids, or combination regimens in refractory cases. For non-exudative AMD, there is no curative treatment, but progression may be slowed with lifestyle modification and nutritional supplementation using AREDS formulations, which include vitamins C and E, zinc, beta-carotene, and copper. Risk factor modification, including smoking cessation and control of cardiovascular risk factors, is essential.
Management of PCV differs somewhat, with photodynamic therapy often playing a central role, particularly for subfoveal lesions. Anti-VEGF therapy is also used but may be less effective compared to its role in AMD, and combination therapy with anti-VEGF agents and photodynamic therapy has shown promising results. Referral to a retinal specialist is essential for both AMD and PCV to ensure appropriate diagnosis and management.
Patients require ongoing monitoring, including regular ophthalmologic evaluations and use of home Amsler grid testing to detect changes in vision. Low vision support may be necessary for those with significant visual impairment. Prognosis varies, with many patients maintaining functional vision with treatment, although both AMD and PCV can lead to progressive central vision loss. Despite this, these conditions do not affect overall lifespan or systemic health.
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among older adults, particularly in developed countries, and is the most common cause of legal blindness in individuals aged 65 years and older in the United States. It is broadly classified into two forms: non-exudative (“dry”) AMD, which accounts for approximately 90% of cases, and exudative (“wet”) AMD, which represents about 10% but is responsible for the majority of severe vision loss. Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity from AMD, characterized by abnormalities in the inner choroidal vasculature, including a branching network of dilated vessels that lead to serous leakage and hemorrhage. PCV is more commonly seen in Asian and African or African American populations, while it is less frequent in Caucasians.
The incidence and prevalence of AMD increase significantly with age. Early AMD rises from about 3.9% in individuals aged 43–54 years to over 20% in those older than 75 years, while late AMD has a 5-year incidence of approximately 0.9%. Overall prevalence of AMD in adults over 40 years is around 9.2%. PCV prevalence varies widely, ranging from 4% to 14%, and may be significantly higher in certain populations, such as Japanese patients diagnosed with AMD. Risk factors for AMD include advancing age, family history, Caucasian race, smoking, hypertension, hyperlipidemia, obesity, and female gender. In contrast, PCV is more strongly associated with ethnicity and age.
Genetic factors play an important role in AMD, with associations identified in genes such as complement factor H (CFH), LOC387715, and HTRA1, with certain variants significantly increasing disease risk. PCV shares some genetic associations, particularly involving LOC387715 and HTRA1. The pathophysiology of AMD is multifactorial and includes degeneration of the retinal pigment epithelium (RPE), accumulation of photoreceptor debris forming drusen, reduced choroidal circulation leading to ischemia, and genetic susceptibility. In the exudative form, abnormal choroidal neovascular membranes develop beneath the retina or RPE, causing leakage and hemorrhage. In PCV, abnormalities in the inner choroidal vasculature result in polyp-like dilations and vascular networks that leak or bleed beneath the RPE.
Patients with AMD or PCV may present with central visual disturbances such as blurring, distortion (metamorphopsia), central scotomas, or may be asymptomatic in early stages. On examination, non-exudative AMD is characterized by drusen, pigmentary changes in the RPE, and eventual retinal thinning or geographic atrophy. Exudative AMD may show subretinal or intraretinal fluid, hemorrhage, lipid exudates, pigment epithelial detachment, or retinal pigment epithelial tears. PCV should be suspected in patients with exudative maculopathy, particularly in non-Caucasian individuals, those with peripapillary lesions, or cases with minimal drusen in the fellow eye.
Diagnosis relies heavily on imaging. Optical coherence tomography (OCT) is essential for identifying fluid, retinal thickening, and monitoring disease progression. Fluorescein angiography is used to identify and characterize choroidal neovascularization in AMD. Indocyanine green angiography is particularly useful in PCV for visualizing the characteristic polypoidal vascular lesions and branching networks. These imaging modalities are also critical in guiding treatment decisions and monitoring response to therapy.
Management of AMD depends on the stage and type of disease. For exudative AMD, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab and ranibizumab are the mainstay of treatment and have significantly improved visual outcomes. Additional therapies may include photodynamic therapy, thermal laser for selected cases, intravitreal steroids, or combination regimens in refractory cases. For non-exudative AMD, there is no curative treatment, but progression may be slowed with lifestyle modification and nutritional supplementation using AREDS formulations, which include vitamins C and E, zinc, beta-carotene, and copper. Risk factor modification, including smoking cessation and control of cardiovascular risk factors, is essential.
Management of PCV differs somewhat, with photodynamic therapy often playing a central role, particularly for subfoveal lesions. Anti-VEGF therapy is also used but may be less effective compared to its role in AMD, and combination therapy with anti-VEGF agents and photodynamic therapy has shown promising results. Referral to a retinal specialist is essential for both AMD and PCV to ensure appropriate diagnosis and management.
Patients require ongoing monitoring, including regular ophthalmologic evaluations and use of home Amsler grid testing to detect changes in vision. Low vision support may be necessary for those with significant visual impairment. Prognosis varies, with many patients maintaining functional vision with treatment, although both AMD and PCV can lead to progressive central vision loss. Despite this, these conditions do not affect overall lifespan or systemic health.
